Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 11/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600347 | 0.86 | SCN10A (0.43) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9980576 | 0.83 | MAPK13 (0.41) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7600434 | 0.80 | BACE1 (0.37) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9977195 | 0.80 | MAPK13 (0.52) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL17014412 | 0.78 | MAPK13 (0.51) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10144846 | 0.78 | MAPK13 (0.51) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7602073 | 0.78 | HPGDS (0.48) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15430158 | 0.76 | MAPK13 (0.41) | HPGDSMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL14867365 | 0.75 | NPC1 (0.41) | HPGDSSCN10ARPS6KB1AKT1CYP1A2 | |
| SCHEMBL7605047 | 0.74 | SCN10A (0.38) | HPGDSMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2418/4885MAPK13 2158/4885MAPK12 2107/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885MAPK13 2347/4885MAPK12 2259/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885MAPK13 2347/4885MAPK12 2259/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885MAPK13 2347/4885MAPK12 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.